Article Text

Download PDFPDF
Lack of association of the pregnane X receptor (PXR/NR1I2) gene with inflammatory bowel disease: parallel allelic association study and gene wide haplotype analysis
  1. G-T Ho1,
  2. N Soranzo2,
  3. S K Tate2,
  4. H Drummond3,
  5. E R Nimmo3,
  6. A Tenesa4,
  7. I D Arnott5,
  8. J Satsangi5
  1. 1Molecular Medicine Centre, Gastrointestinal Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK
  2. 2Department of Clinical and Experimental Epilepsy, Institute of Neurology, London, UK
  3. 3Molecular Medicine Centre, Gastrointestinal Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK
  4. 4MRC Human Genetics Unit, Edinburgh, UK
  5. 5Molecular Medicine Centre, Gastrointestinal Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK
  1. Correspondence to:
    Dr G-T Ho
    Molecular Medicine Unit, Gastrointestinal Unit, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK; gwotzerho{at}aol.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The pregnane X receptor gene (PXR/NR1I2) regulates an array of genes involved in the response to xenobiotics.1,2 Dysregulation of this gene may critically influence intestinal barrier defence and susceptibility to inflammatory bowel disease (IBD).3 Recent data from Ireland have suggested strong associations between polymorphisms within the PXR/NR1I2 gene and IBD. Dring et al performed a case control study involving 422 patients with IBD (185 ulcerative colitis (UC) and 237 (Crohn’s disease (CD)) and 350 healthy controls, using eight candidate polymorphisms in this gene.4 Highly significant associations were demonstrated with UC, CD, and IBD as a whole. This effect was most significant for the two individual single nucleotide polymorphisms (SNPs) in the promoter region of this gene; compared between the IBD cohort and controls, rs3814055/−23585 (p = 0.000008; odds ratio (OR) 1.62 (95% confidence interval (CI) 1.31–2.00)) and rs1523127/−24381 (p = 0.0002; OR 1.50 (95% CI 1.21–1.84)).

We have critically re-evaluated the contribution of these allelic variants …

View Full Text

Footnotes

  • Dr Gwo-Tzer Ho was supported by the Chief Scientist’s Office, Scottish Executive, UK (2001-04). Dr Albert Tenesa is funded by Cancer Research UK grant C348/A3758. Dr Elaine Nimmo and Mrs Hazel Drummond are supported by a program grant from the Wellcome Trust, C72789/Z/03/Z.

  • Conflict of interest: None declared.